A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients with Parkinson’s Disease with at Least One GBA1 Mutation (PROPEL)

Status

Withdrawn

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519587-40-00

Acronym

J3Z-MC-OJAA

Enrollment

Registered

2025-06-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson’s Disease with at Least One GBA1 Mutation

Brief summary

Incidence and severity of treatment-emergent AEs and SAE, Incidence of procedure or treatment-emergent safety findings, Treatment emergent and change from baseline in immunogenicity of adeno-associated viruses serotype 9 and glucocerebrosidase

Detailed description

Change from baseline in glycolipid and glucocerebrosidase levels, as well as glucocerebrosidase enzyme activity in blood, Change from baseline in glycolipid and glucocerebrosidase levels, as well as glucocerebrosidase enzyme activity in cerebrospinal fluid

Interventions

DRUGLY3884961

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence and severity of treatment-emergent AEs and SAE, Incidence of procedure or treatment-emergent safety findings, Treatment emergent and change from baseline in immunogenicity of adeno-associated viruses serotype 9 and glucocerebrosidase	—

Secondary

Measure	Time frame
Change from baseline in glycolipid and glucocerebrosidase levels, as well as glucocerebrosidase enzyme activity in blood, Change from baseline in glycolipid and glucocerebrosidase levels, as well as glucocerebrosidase enzyme activity in cerebrospinal fluid	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026